FIELD: chemistry.
SUBSTANCE: invention relates to compounds of formula (I) or (II)
including enantiomer or diastereomer thereof, where values of R1, R2, R3, R100, R200, R300, A, A1, BG, Q and Q1 are given in claim 1.
EFFECT: compounds can be used to treat proliferative disorders, for example, cancer.
42 cl, 36 dwg, 7 tbl
Title | Year | Author | Number |
---|---|---|---|
COMPOUNDS BOUND WITH BIR DOMAIN OF IAP | 2007 |
|
RU2446170C2 |
COMPOUNDS BINDING IAP BIR DOMAINS | 2006 |
|
RU2418807C2 |
BIR DOMAIN IAP BINDING COMPOUNDS | 2011 |
|
RU2567544C2 |
IAP INHIBITORS | 2005 |
|
RU2401840C2 |
ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | 2015 |
|
RU2707749C2 |
ESTROGEN RECEPTOR PROTEOLYSIS MODULATORS AND RELATED USES THEREOF | 2018 |
|
RU2797808C2 |
TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DESTROYERS | 2017 |
|
RU2797244C2 |
KINASE INHIBITORS | 2012 |
|
RU2623734C9 |
IMIDAZOPYRIDINE IAP INHIBITORS | 2007 |
|
RU2466131C2 |
IAP INHIBITORS | 2008 |
|
RU2491276C2 |
Authors
Dates
2013-01-20—Published
2007-03-16—Filed